Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.

Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001725160-24-000036 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-02-05	2024-02-01	ZNTL	HAUSMAN DIANA	Chief Medical Off	A - Grant	$0.00	+337.5K	377.2K	+849%	$0
D	2024-02-05	2024-02-01	ZNTL	HAUSMAN DIANA	Chief Medical Off	A - Grant	$0.00	+337.5K	337.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-01	A	A	337,500	$0.00	377,232	D	—	—	(F1) Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer.
2	Derivative	Stock Option (Right to Buy)	2024-02-01	A	A	337,500	$0.00	337,500	D	$11.69 · — to 2034-01-31	337,500 Common Stock	(F2) The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.